. 2021 Mar 30;6(6):1537–1547. doi: 10.1016/j.ekir.2021.03.889

Table 1.

Demographic and clinical characteristics by CKD and CR status

Characteristic	Referred to CR but did not start		Started CR but did not complete		Completed CR
Characteristic	No CKD	CKD	No CKD	CKD	No CKD	CKD
N	2876 (82.9)	592 (17.1)	3109 (91.1)	305 (8.9)	4777 (91.8)	425 (8.2)
Age, yr	63 [55–71]^a	74 [68–80]^a	59 [52–66]^a	71 [64–77]^a	59 [53–67]^a	71 [64–77]^a
Female sex	630 (21.9)	187 (31.6)^a	595 (19.1)^a	83 (27.2)^a	791 (16.6)^a	94 (22.1)^a
South Asian	257 (8.9)	40 (6.8)	264 (8.5)^a	15 (4.9)^a	375 (7.9)^a	21 (4.9)^a
Distance to CR center	10 [5–30]	10 [5–30]	15 [10–25]	15 [10–25]	15 [10–25]^a	10 [10–15]^a
Rural	187 (6.6)	36 (6.1)	129 (4.2)	11 (3.6)	132 (2.8)	10 (2.4)
Social assistance	106 (3.7)	17 (2.9)	78 (2.5)	11 (3.6)	63 (1.3)	4 (0.9)
Low-income neighborhood	732 (25.5)	137 (23.1)	629 (20.2)	49 (16.1)	756 (15.8)^a	51 (12.0)^a
Era
1996–2005	440 (15.3)^a	99 (16.7)^a	172 (5.5)	16 (5.2)	913 (19.1)^a	86 (20.2)^a
2006–2010	1433 (49.8)^a	251 (42.4)^a	660 (21.2)	76 (24.9)	2033 (42.6)^a	204 (48.0)^a
2011–2016	1003 (34.9)^a	242 (40.9)^a	2277 (73.2)	213 (69.8)	1831 (38.3)^a	135 (31.8)^a
Smoker	1046 (36.4)^a	106 (17.9)^a	1035 (33.3)^a	50 (16.4)^a	1166 (24.4)^a	45 (10.6)^a
Days from catheterization to program referral	6 [2–32]^a	18 [5–62]^a	4 [2–9]^a	7 [3–23]^a	5 [3–15]^a	9 [3–47]^a
Referral due to ACS	1966 (68.4)^a	341 (57.6)^a	2370 (76.2)^a	192 (63.0)^a	3612 (75.6)^a	272 (64.0)^a
Days from catheterization to program start	—	—	54 [34–97]^a	77 [42–138]^a	74 [39–111]^a	94 [62–147]^a
Days from catheterization to follow-up	—	—	120 [92–165]^a	133 [95–181]^a	130 [95–168]^a	150 [118–203]^a
CAD severity
1-vessel	1011 (35.2)^a	129 (21.8)^a	1222 (39.3)^a	83 (27.2)^a	1860 (38.9)^a	132 (31.1)^a
2-vessel	874 (30.4)^a	171 (28.9)^a	1001 (32.2)^a	94 (30.8)^a	1472 (30.8)^a	120 (28.2)^a
3-vessel	757 (26.3)^a	216 (36.5)^a	775 (24.9)^a	101 (33.1)^a	1188 (24.9)^a	134 (31.5)^a
Left main	234 (8.1)^a	76 (12.8)^a	111 (3.6)^a	27 (8.9)^a	257 (5.4)^a	39 (9.2)^a
Exercise capacity (METs)	—	—	7.0 [5.7–8.7]^a	5.1 [3.8–7.0]^a	7.7 [6.4–9.0]^a	6.4 [5.0–7.7]^a
eGFR, mL/min/1.73 m²	87 [76–97]^a	49 [40–56]^a	91 [80–100]^a	50 [42–55]	89 [78–98]^a	52 [45–56]^a
45–59	—	377 (63.7)	—	206 (67.5)	—	320 (75.3)
30–44	—	145 (24.5)	—	68 (22.3)	—	79 (18.6)
15–29	—	38 (6.4)	—	13 (4.3)	—	13 (3.1)
<15 or RRT	—	32 (5.4)	—	18 (5.9)	—	13 (3.1)
Comorbidity
Albuminuria	205 (7.1)^a	126 (21.3)^a	171 (5.5)^a	69 (22.6)^a	196 (4.1)^a	68 (16.0)^a
Alcohol misuse	160 (5.6)	22 (3.7)	140 (4.5)	11 (3.6)	110 (2.3)	6 (1.4)
Atrial fibrillation	245 (8.5)^a	126 (21.3)^a	163 (5.2)^a	40 (13.1)^a	308 (6.4)^a	52 (12.2)^a
Metastatic cancer	142 (4.9)^a	42 (7.1)^a	118 (3.8)^a	21 (6.9)^a	154 (3.2)^a	26 (6.1)^a
Chronic heart failure	244 (8.5)^a	145 (24.5)^a	149 (4.8)^a	53 (17.4)^a	238 (5.0)^a	57 (13.4)^a
COPD	462 (16.1)^a	151 (25.5)^a	361 (11.6)^a	53 (17.4)^a	477 (10.0)^a	75 (17.6)^a
Depression	296 (10.3)	62 (10.5)	293 (9.4)	27 (8.9)	397 (8.3)	34 (8.0)
Diabetes	766 (26.6)^a	244 (41.2)^a	708 (22.8)^a	107 (35.1)^a	861 (18.0)^a	110 (25.9)^a
Hypertension	1961 (68.2)^a	500 (84.5)^a	1860 (59.8)^a	234 (76.7)^a	2864 (60.0)^a	333 (78.4)^a
Hyperlipidemia	2081 (72.4)	432 (73.0)	2007 (64.6)	198 (64.9)	3312 (69.3)	295 (69.4)
Obesity	790 (28.2)	141 (24.9)	927 (31.3)	84 (28.2)	1304 (28.4)	118 (28.6)
PVD	188 (6.5)^a	60 (10.1)^a	150 (4.8)^a	25 (8.2)^a	179 (3.7)^a	35 (8.2)^a
Stroke	148 (5.1)^a	61 (10.3)^a	92 (3.0)^a	29 (9.5)^a	121 (2.5)^a	25 (5.9)^a

ACS, acute coronary syndrome; CAD, coronary artery disease; CKD, chronic kidney disease; CR, cardiac rehabilitation; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; MET, metabolic equivalent of task; PVD, peripheral vascular disease; RRT, renal replacement therapy.

Data shown as n (%) or median [interquartile range].

Indicates that Fisher exact or Kruskal-Wallis test was significant (P < 0.05).